Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction TPFL and Chemoradiotherapy in Head and Neck Cancer
NCT00544414Phase 2Completed
- Sponsor
- City of Hope
- Start
- Jun 2000
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin, fluorouracil and gemcitabine in head and neck cancer (HNC), sponsored by City of Hope. Primary endpoints: Overall Response, Progression-free Survival up to 171 months and 2 more. Started Jun 2000; status: completed.
02
Drugs
docetaxelcisplatinfluorouracilgemcitabine
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00544414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00544414.